RESUMEN
Previous research on histamine H(3) antagonists has led to the development of a pharmacophore model consisting of a central phenyl core flanked by two alkylamine groups. Recent investigation of the replacement of the central phenyl core with heteroaromatic fragments resulted in the preparation of novel 3,5-, 3,6- and 3,7-substituted indole and 3,5-substituted benzothiophene analogs that demonstrate good to excellent hH(3) affinities. Select analogs were profiled in a rat pharmacokinetic model.
Asunto(s)
Antagonistas de los Receptores Histamínicos H3/síntesis química , Antagonistas de los Receptores Histamínicos H3/farmacología , Indoles/síntesis química , Indoles/farmacología , Tiofenos/síntesis química , Tiofenos/farmacología , Animales , Canales de Potasio Éter-A-Go-Go/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Indicadores y Reactivos , Indoles/farmacocinética , Isomerismo , Modelos Moleculares , Ratas , Relación Estructura-Actividad , Tiofenos/farmacocinéticaRESUMEN
A novel series of imidazole containing histamine H(3) receptor ligands were investigated and found to be potent functional antagonists. After improving the stability of these molecules towards liver microsomes, these compounds were found to have no appreciable affinity for CYP P450s. Subsequent in vivo experiments showed significant brain uptake of (4-chloro-phenyl)-[2-(1-isopropyl-piperidin-4-ylmethoxy)-3-methyl-3H-imidazol-4-yl]-methanone 22.
Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Encéfalo/efectos de los fármacos , Química Farmacéutica/métodos , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/síntesis química , Imidazoles/química , Animales , Encéfalo/metabolismo , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Cobayas , Antagonistas de los Receptores Histamínicos H3/metabolismo , Humanos , Ligandos , Modelos Químicos , Unión Proteica , Ratas , Relación Estructura-ActividadRESUMEN
The synthesis and biological activity of a new series of piperazine and diazepane amides is described. The new compounds are high affinity histamine H3 ligands and serotonin reuptake inhibitors.
Asunto(s)
Azepinas/síntesis química , Antagonistas de los Receptores Histamínicos H3/síntesis química , Piperazinas/síntesis química , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Amidas/síntesis química , Amidas/farmacocinética , Amidas/farmacología , Animales , Azepinas/farmacocinética , Azepinas/farmacología , Encéfalo/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Antagonistas de los Receptores Histamínicos H3/farmacología , Humanos , Piperazinas/farmacocinética , Piperazinas/farmacología , Ratas , Inhibidores Selectivos de la Recaptación de Serotonina/farmacocinética , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Relación Estructura-ActividadRESUMEN
Wake-promoting agents such as modafinil are used in the clinic as adjuncts to antidepressant therapy in order to alleviate lethargy. The wake-promoting action of histamine H(3) receptor antagonists has been evidenced in numerous animal studies. They may therefore be a viable strategy for use as an antidepressant therapy in conjunction with selective serotonin reuptake inhibitors. JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters. After subcutaneous administration, JNJ-28583867 occupied both the histamine H(3) receptor and the SERT in rat brain at low doses (<1 mg/kg). JNJ-28583867 blocked imetit-induced drinking (3-10 mg/kg i.p.), confirming in vivo functional activity at the histamine H(3) receptor and also significantly increased cortical extracellular levels of serotonin at doses of 0.3 mg/kg (s.c.) and higher. Smaller increases in cortical extracellular levels of norepinephrine and dopamine were also observed. JNJ-28583867 (3-30 mg/kg p.o.) showed antidepressant-like activity in the mouse tail suspension test. JNJ-28583867 (1-3 mg/kg s.c.) caused a dose-dependent increase in the time spent awake mirrored by a decrease in NREM. Concomitantly, JNJ-28583867 produced a potent suppression of REM sleep from the dose of 1 mg/kg onwards. JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o. In summary, JNJ-28583867 is a combined histamine H(3) receptor antagonist-SERT inhibitor with in vivo efficacy in biochemical and behavioral models of depression and wakefulness.
Asunto(s)
Antagonistas de los Receptores Histamínicos/farmacología , Receptores Histamínicos H3/metabolismo , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Tetrahidroisoquinolinas/farmacología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Células CHO , Línea Celular , Cricetinae , Cricetulus , Perros , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Antagonistas de los Receptores Histamínicos/farmacocinética , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/metabolismo , Ratas , Ratas Sprague-Dawley , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Inhibidores Selectivos de la Recaptación de Serotonina/farmacocinética , Tetrahidroisoquinolinas/farmacocinéticaRESUMEN
Two new series of 4-(1-alkyl-piperidin-4-yloxy)-benzonitriles and 4-(1-isopropyl-piperidin-4-yloxy)-benzylamines have been prepared. In vitro activity was determined at the recombinant human H(3) receptor and several members of these new series were found to be potent H(3) antagonists. The present compounds contain a 4-phenoxypiperidine core, which behaves as a conformationally restricted version of the 3-amino-1-propanol moiety common to the many previously described non-imidazole histamine H(3) ligands. One selected member of the new series, 4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-morpholine (13g), was found to be a potent, highly selective H(3) receptor antagonist with in vivo efficacy in a rat EEG model of wakefulness at doses as low as 1 mg/kg sc.
Asunto(s)
Antagonistas de los Receptores Histamínicos/síntesis química , Piperidinas/síntesis química , Receptores Histamínicos H3/efectos de los fármacos , Animales , Autorradiografía , Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Línea Celular , Electroencefalografía , Electromiografía , Antagonistas de los Receptores Histamínicos/química , Antagonistas de los Receptores Histamínicos/farmacología , Humanos , Masculino , Conformación Molecular , Piperidinas/química , Piperidinas/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Sueño/efectos de los fármacos , Relación Estructura-Actividad , Vigilia/efectos de los fármacosRESUMEN
4-(Aminoalkoxy)benzylamines were prepared and screened for in vitro activity at the human histamine H(3) receptor. Some members of this series exhibited subnanomolar binding affinities. Analogues in which one nitrogen atom was replaced with a methine group showed greatly reduced binding affinities. Six members of this series were found to be antagonists in a cell-based model of human histamine H(3) receptor activation. One member of this series, 1-[4-(3-piperidin-1-ylpropoxy)benzyl]piperidine (7b), was found to be a selective and potent human H(3) receptor antagonist.
Asunto(s)
Bencilaminas/síntesis química , Antagonistas de los Receptores Histamínicos/síntesis química , Piperidinas/síntesis química , Receptores Histamínicos H3/efectos de los fármacos , Animales , Bencilaminas/metabolismo , Bencilaminas/farmacología , Células CACO-2 , Línea Celular , Corteza Cerebral/metabolismo , AMP Cíclico/biosíntesis , Antagonistas de los Receptores Histamínicos/metabolismo , Antagonistas de los Receptores Histamínicos/farmacología , Humanos , Técnicas In Vitro , Permeabilidad , Piperidinas/metabolismo , Piperidinas/farmacología , Ratas , Receptores Histamínicos H3/metabolismo , Relación Estructura-ActividadRESUMEN
The role of 5-HT7 receptor has been demonstrated in various animal models of mood disorders; however its function in cognition remains largely speculative. This study evaluates the effects of SB-269970, a selective 5-HT7 antagonist, in a translational model of working memory deficit and investigates whether it modulates cortical glutamate and/or dopamine neurotransmission in rats. The effect of SB-269970 was evaluated in the delayed non-matching to position task alone or in combination with MK-801, a non-competitive NMDA receptor antagonist, and, in separate experiments, with scopolamine, a non-selective muscarinic antagonist. SB-269970 (10 mg/kg) significantly reversed the deficits induced by MK-801 (0.1 mg/kg) but augmented the deficit induced by scopolamine (0.06 mg/kg). The ability of SB-269970 to modulate MK-801-induced glutamate and dopamine extracellular levels was separately evaluated using biosensor technology and microdialysis in the prefrontal cortex of freely moving rats. SB-269970 normalized MK-801 -induced glutamate but not dopamine extracellular levels in the prefrontal cortex. Rat plasma and brain concentrations of MK-801 were not affected by co-administration of SB-269970, arguing for a pharmacodynamic rather than a pharmacokinetic mechanism. These results indicate that 5-HT7 receptor antagonists might reverse cognitive deficits associated with NMDA receptor hypofunction by selectively normalizing glutamatergic neurotransmission.
Asunto(s)
Corteza Cerebral/metabolismo , Ácido Glutámico/metabolismo , Trastornos de la Memoria/tratamiento farmacológico , Memoria a Corto Plazo/efectos de los fármacos , Receptores de Serotonina/metabolismo , Transmisión Sináptica/efectos de los fármacos , Animales , Corteza Cerebral/efectos de los fármacos , Maleato de Dizocilpina/farmacocinética , Maleato de Dizocilpina/uso terapéutico , Masculino , Trastornos de la Memoria/metabolismo , Fenoles/farmacocinética , Fenoles/uso terapéutico , Ratas , Ratas Sprague-Dawley , Antagonistas de la Serotonina/farmacocinética , Antagonistas de la Serotonina/uso terapéutico , Sulfonamidas/farmacocinética , Sulfonamidas/uso terapéuticoRESUMEN
Histamine 3 (H(3)) receptors are distributed throughout the brain and regulate histamine as well as the activity of other neurotransmitters including acetylcholine (ACh). Impaired ACh neurotransmission is associated with deficits of cognitive-related functioning in many species including humans. The goal of these studies was to evaluate the behavioral and neurochemical effects of JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, in rats. The pharmacokinetic profile and receptor occupancy of JNJ-10181457 were tested. The efficacy of JNJ-10181457 was evaluated, acutely, in the imetit-induced water licking model, delayed non-matching to position (DNMTP) task and microdialysis studies. In addition, the effects of repeated administration of JNJ-10181457 were evaluated in the reversal learning task. A single administration of JNJ-10181457 (10 mg/kg, i.p.) resulted in significant plasma and brain exposure and maximal H(3) receptor occupancy. In addition, JNJ-10181457 reversed imetit-induced water licking, similarly to thioperamide (10 mg/kg, i.p.). In the DNMTP task, scopolamine (0.06 mg/kg, i.p.) significantly decreased percentage correct responding. These effects were significantly reversed by JNJ-10181457 (10 mg/kg, i.p.) and also by donepezil (1 mg/kg, i.p.), an acetylcholinesterase inhibitor, and were associated with normalization of ACh neurotransmission in the cortex. Repeated administration of JNJ-10181457 (10 mg/kg, i.p.) significantly increased percentage correct responding in the reversal learning task. Treatment discontinuation was not associated with rebound effects on cognition. These results indicate that selective blockade of histamine H(3) receptors might have therapeutic utility for the treatment of working memory deficits and learning disorders, especially those in which ACh neurotransmission is compromised.
Asunto(s)
Acetilcolina/metabolismo , Cognición/efectos de los fármacos , Antagonistas de los Receptores Histamínicos/farmacología , Morfolinas/farmacología , Nootrópicos/farmacología , Piperidinas/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Animales , Anticonvulsivantes/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Inhibidores de la Colinesterasa/farmacología , Cognición/fisiología , Condicionamiento Operante/efectos de los fármacos , Donepezilo , Conducta de Ingestión de Líquido/efectos de los fármacos , Conducta de Ingestión de Líquido/fisiología , Evaluación Preclínica de Medicamentos , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos/farmacocinética , Imidazoles/farmacología , Indanos/farmacología , Aprendizaje/efectos de los fármacos , Aprendizaje/fisiología , Microdiálisis , Morfolinas/farmacocinética , Antagonistas Muscarínicos/farmacología , Nootrópicos/farmacocinética , Piperidinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Escopolamina/farmacología , Transmisión Sináptica/fisiología , Tiourea/análogos & derivados , Tiourea/farmacologíaRESUMEN
A series of small molecules consisting of a heterocyclic core flanked by two basic functionalities were synthesized and screened for in vitro affinity at the human histamine H(3) receptor (hH(3)R). Nine of the twenty-eight compounds tested were found to possess a hH(3)R K(i) of less than 5 nM and consisted of a diverse range of central hetero-aromatic linkers (pyridine, pyrazine, oxazole, isoxazole, thiazole, furan, thiophene, and pyrrole). One member of this series, (4-isopropyl-piperazin-1-yl)-(6-piperidin-1-ylmethyl-pyridin-3-yl)-methanone (37), was found to be a high affinity, selective antagonist that crosses the blood-brain barrier and occupies H(3) receptors after oral administration in the rat.
Asunto(s)
Diaminas/química , Diaminas/farmacología , Antagonistas de los Receptores Histamínicos H3/química , Antagonistas de los Receptores Histamínicos H3/farmacología , Receptores Histamínicos H3/metabolismo , Animales , Barrera Hematoencefálica/efectos de los fármacos , Línea Celular , Diaminas/farmacocinética , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Humanos , Unión Proteica , Ratas , Ratas Sprague-DawleyRESUMEN
5-HT7 receptors have been linked to a number of psychiatric disorders including anxiety and depression. The localization of 5-HT7 receptors in the thalamus, a key sensory processing center, and the high affinity of many atypical antipsychotic compounds for these receptors have led to the speculation of the utility of 5-HT7 antagonists in schizophrenia. The goal of these studies was to examine the effects of pharmacologic blockade and genetic ablation of 5-HT7 receptors in animal models predictive of antipsychotic-like activity. We evaluated the effects of SB-269970, a selective 5-HT7 receptor antagonist, on amphetamine and ketamine-induced hyperactivity and prepulse inhibition (PPI) deficits. In addition, sensorimotor gating function and locomotor activity were evaluated in 5-HT7 knockout mice. Locomotor activity was measured for up to 180 min using an automated infrared photobeam system, and PPI was evaluated in startle chambers. SB-269970 (3, 10 and 30 mg/kg, intraperitoneally) significantly blocked amphetamine [3 mg/kg, subcutaneously (s.c.)] and ketamine (30 mg/kg, s.c.)-induced hyperactivity and reversed amphetamine (10 mg/kg, s.c.)-induced but not ketamine (30 mg/kg, s.c.)-induced PPI deficits, without changing spontaneous locomotor activity and startle amplitude. The largest dose of SB-269970 did not block the effects of amphetamine in 5-HT7 knockout mice. Collectively, these results indicate that blockade of 5-HT7 receptors partially modulates glutamatergic and dopaminergic function and could be clinically useful for the treatment of positive symptoms of schizophrenia.
Asunto(s)
Antipsicóticos/farmacología , Encéfalo/efectos de los fármacos , Modelos Animales de Enfermedad , Fenoles/farmacología , Trastornos Psicóticos/psicología , Receptores de Serotonina/efectos de los fármacos , Sulfonamidas/farmacología , Anfetamina/farmacología , Animales , Nivel de Alerta/efectos de los fármacos , Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Glutamina/metabolismo , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Ketamina/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Actividad Motora/efectos de los fármacos , Receptores de Serotonina/genética , Reflejo de Sobresalto/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacosRESUMEN
The design, synthesis, and in vitro activity of a series of novel 5-ethynyl-2-aryloxybenzylamine-based histamine H(3) ligands that are also serotonin reuptake transporters is described.
Asunto(s)
Bencilaminas/química , Química Farmacéutica/métodos , Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/farmacología , Receptores Histamínicos H3/química , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Animales , Antidepresivos/farmacología , Diseño de Fármacos , Humanos , Cinética , Modelos Químicos , Unión Proteica , Ratas , Inhibidores Selectivos de la Recaptación de Serotonina/químicaRESUMEN
A series of novel and potent 6-heteroaryl-pyrrolidino-tetrahydroisoquinolines with dual histamine H(3) antagonist/serotonin transporter inhibitor activity is described. In vitro and in vivo data are discussed.
Asunto(s)
Antagonistas de los Receptores Histamínicos H1/farmacología , Pirrolidinas/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Proteínas de Transporte de Serotonina en la Membrana Plasmática/efectos de los fármacos , Tetrahidroisoquinolinas/farmacología , Animales , Barrera Hematoencefálica , Antagonistas de los Receptores Histamínicos H1/química , Ratones , Pirrolidinas/química , Relación Estructura-Actividad , Tetrahidroisoquinolinas/químicaRESUMEN
A series of novel tetrahydronaphthyridine-based histamine H(3) ligands that have serotonin reuptake transporter inhibitor activity is described. The 1,2,3,4-tetrahydro-2,6-naphthyridine scaffold is assembled via the addition of a nitrostyrene to a metalated pyridine followed by reduction and cyclization to form the naphthyridine. In vitro biological data for these novel compounds are discussed.
Asunto(s)
Química Farmacéutica/métodos , Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/farmacología , Histamina/química , Naftiridinas/síntesis química , Receptores Histamínicos H3/química , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Animales , Diseño de Fármacos , Humanos , Modelos Químicos , Conformación Molecular , Naftiridinas/farmacología , Ratas , Serotonina/metabolismo , Inhibidores Selectivos de la Recaptación de Serotonina/farmacologíaRESUMEN
The synthesis and structure-activity relationships of a series of novel phenoxyphenyl diamine derivatives with affinity for both the histamine H(3) receptor and the serotonin transporter is described.
Asunto(s)
Diaminas/química , Antagonistas de los Receptores Histamínicos/química , Antagonistas de los Receptores Histamínicos/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/química , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Antagonistas de los Receptores Histamínicos/síntesis química , Humanos , Estructura Molecular , Receptores Histamínicos H3/química , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Relación Estructura-ActividadRESUMEN
A series of tetrahydroisoquinolines acting as dual serotonin transporter inhibitor/histamine H(3) antagonists is described. The introduction of polar aromatic spacers as part of the histamine H(3) pharmacophore was explored. A convergent synthesis of the final products allowing late stage introduction of the aromatic side chain was developed. In vitro and in vivo data are discussed.
Asunto(s)
Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Antagonistas de la Serotonina/síntesis química , Antagonistas de la Serotonina/farmacología , Proteínas de Transporte de Serotonina en la Membrana Plasmática/efectos de los fármacos , Tetrahidroisoquinolinas/síntesis química , Tetrahidroisoquinolinas/farmacología , 5-Hidroxitriptófano/farmacología , Animales , Encéfalo/metabolismo , Diseño de Fármacos , Humanos , Indicadores y Reactivos , Ratas , Relación Estructura-ActividadRESUMEN
A series of tetrahydroisoquinolines acting as dual histamine H3/serotonin transporter ligands is described. A highly regio-selective synthesis of the tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH3 was developed. In vitro and in vivo data are discussed.
Asunto(s)
Receptores Histamínicos H3/química , Receptores Histamínicos H3/efectos de los fármacos , Proteínas de Transporte de Serotonina en la Membrana Plasmática/efectos de los fármacos , 5-Hidroxitriptófano/farmacología , Animales , Conducta Animal/efectos de los fármacos , Humanos , Isoquinolinas/síntesis química , Isoquinolinas/farmacología , Ligandos , Ratones , Piperazinas/síntesis química , Piperazinas/farmacología , Ratas , Relación Estructura-ActividadRESUMEN
A series of novel and potent pyrrolidino-tetrahydroisoquinolines with dual histamine H(3) antagonist/serotonin transporter inhibitor activity is described. A highly regio- and diastereoselective synthesis of the pyrrolidino-tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH(3) was developed. In vitro and in vivo data are discussed.
Asunto(s)
Química Farmacéutica/métodos , Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/farmacología , Receptores Histamínicos H3/química , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Serotonina/química , Tetrahidroisoquinolinas/síntesis química , Tetrahidroisoquinolinas/farmacología , Animales , Depresión/tratamiento farmacológico , Diseño de Fármacos , Humanos , Cinética , Modelos Químicos , Conformación Molecular , RatasRESUMEN
A series of novel 4-aryl-1,2,3,4-tetrahydroisoquinoline-based histamine H(3) ligands that also have serotonin reuptake transporter inhibitor activity is described. The synthesis, in vitro biological data, and select pharmacokinetic data for these novel compounds are discussed.
Asunto(s)
Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Tetrahidroisoquinolinas/síntesis química , Tetrahidroisoquinolinas/farmacología , Animales , Cristalografía por Rayos X , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/efectos de los fármacos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Semivida , Humanos , Indicadores y Reactivos , Modelos Moleculares , Conformación Molecular , Norepinefrina/metabolismo , Ratas , Proteínas de Transporte de Serotonina en la Membrana Plasmática/efectos de los fármacos , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Inhibidores Selectivos de la Recaptación de Serotonina/farmacocinética , Relación Estructura-Actividad , Tetrahidroisoquinolinas/farmacocinéticaRESUMEN
Aplysamine-1 (1), a marine natural product, was synthesized and screened for in vitro activity at the human and rat histamine H3 receptors. Aplysamine-1 (1) was found to possess a high binding affinity for the human H3 receptor (Ki = 30+/-4 nM). Synthetic analogs of 1, including des-bromoaplysamine-1 (10) and dimethyl-{2-[4-(3-piperidin-1-yl-propoxy)-phenyl]-ethyl}-amine (13), were potent H3 antagonists.